"In June 2003, the PCPT was stopped early because of a clear finding that finasteride reduced the incidence of prostate cancer. However, those trial participants who did develop prostate cancer while taking finasteride experienced a slightly higher incidence of high-grade tumors. Researchers are continuing to analyze the data to find out whether finasteride actually caused high-grade tumors."
http://www.nci.nih.gov/pcpt
"N Engl J Med 2003 Jul 17;349(3):215-24 (ISSN: 1533-4406)
Thompson IM; Goodman PJ; Tangen CM; Lucia MS; Miller GJ; Ford LG; Lieber MM; Cespedes RD; Atkins JN; Lippman SM; Carlin SM; Ryan A; Szczepanek CM; Crowley JJ; Coltman CA
University of Texas Health Science Center, San Antonio, USA.
BACKGROUND: Androgens are involved in the development of prostate cancer. Finasteride, an inhibitor of 5alpha-reductase, inhibits the conversion of testosterone to dihydrotestosterone, the primary androgen in the prostate, and may reduce the risk of prostate cancer. METHODS: In the Prostate Cancer Prevention Trial, we randomly assigned 18,882 men 55 years of age or older with a normal digital rectal examination and a prostate-specific antigen (PSA) level of 3.0 ng per milliliter or lower to treatment with finasteride (5 mg per day) or placebo for seven years. Prostate biopsy was recommended if the annual PSA level, adjusted for the effect of finasteride, exceeded 4.0 ng per milliliter or if the digital rectal examination was abnormal. It was anticipated that 60 percent of participants would have prostate cancer diagnosed during the study or would undergo biopsy at the end of the study. The primary end point was the prevalence of prostate cancer during the seven years of the study. RESULTS: Prostate cancer was detected in 803 of the 4368 men in the finasteride group who had data for the final analysis (18.4 percent) and 1147 of the 4692 men in the placebo group who had such data (24.4 percent), for a 24.8 percent reduction in prevalence over the seven-year period (95 percent confidence interval, 18.6 to 30.6 percent; P<0.001). Tumors of Gleason grade 7, 8, 9, or 10 were more common in the finasteride group (280 of 757 tumors [37.0 percent], or 6.4 percent of the 4368 men included in the final analysis) than in the placebo group (237 of 1068 tumors [22.2 percent], P<0.001 for the comparison between groups; or 5.1 percent of the 4692 men included in the final analysis, P=0.005 for the comparison between groups). Sexual side effects were more common in finasteride-treated men, whereas urinary symptoms were more common in men receiving placebo. CONCLUSIONS: Finasteride prevents or delays the appearance of prostate cancer, but this possible benefit and a reduced risk of urinary problems must be weighed against sexual side effects and the increased risk of high-grade prostate cancer. [Copyright 2003 Massachusetts Medical Society].
"
de Gaulle said:
jkriley,
Adding 25% more finasteride in your body than you would normally have while using Propecia is certainly not helping you with the side effects!
I can't believe Doctors take the risk to prescribe Proscar to people who don't have Prostate cancer!!
Everybody think Merck is just a money making firm with no ethic and therfore they produce an overpriced drug, Propecia, with a lower dosage of finasteride but with the same side effects Proscar has?!
Come on boys, I believe Merck did some serious research and if 1mg was the dosage prescribed to treat hairloss, that is that there must be some good reason to it!?
de Gaulle.